Mar 09, 2021 / 12:00PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Good day, and thanks for joining us to have a conversation with Jaume Pons, CEO; and Sophia Randolph, CMO of ALX Oncology. ALX Oncology is developing novel antibodies targeting the CD47-SIRPalpha axis. This -- their lead asset, ALX148, is being tested in the clinic as a therapy for treating solid tumors, a first for anti-CD47 therapies.
To discuss the clinical development to date, the expected progress in 2021 and beyond, I welcome Jaume and Sophia to this fireside chat. Jaume and Sophia, glad to see you both and accepting our invitation to talk to our audience today.
Jaume Pons - ALX Oncology Holdings Inc. - President, CEO & Director
Thank you.
Sophia Randolph - ALX Oncology Holdings Inc. - Chief Medical Officer
Thank you.
ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat Transcript
Mar 09, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers